Grup Farmasi & Layanan Kesehatan Terintegrasi
Kami berkomitmen untuk menjadi perusahaan solusi layanan kesehatan global yang terkemuka, dengan terus berinovasi guna menghadirkan beragam produk berkualitas tinggi.
Didorong oleh komitmen ini, kami memajukan riset dan pengembangan untuk menciptakan solusi layanan kesehatan yang andal dan efektif, membangun kolaborasi yang kuat dengan mitra global tepercaya, serta mengembangkan sumber daya manusia yang adaptif dan sangat terampil guna memenuhi kebutuhan masyarakat dunia yang terus berkembang.
Group Kami
PT Pyridam Farma Tbk
The Strategic Growth Driver
Didirikan pada tahun 1976 dan tercatat secara publik di Bursa Efek Indonesia sejak tahun 2001 (IDX: PYFA), Pyridam Farma berperan sebagai perusahaan induk sekaligus penggerak strategis Grup. Seiring berjalannya waktu, PYFA telah bertransformasi dari produsen obat resep konvensional menjadi platform layanan kesehatan regional yang terintegrasi dengan portofolio terdiversifikasi di bidang farmasi, kesehatan konsumen, serta segmen spesialisasi, memosisikan dirinya sebagai grup investasi layanan kesehatan yang siap menghadapi masa depan di kawasan Asia-Pasifik.
Manufacturing Capacity & Capabilities
Location
Cianjur, West Java – Indonesia
Total Area
35,000 sqm
Buildings
4 Production Units
Facility Scope
Non-Beta Lactam, Betalactam, Cosmetic
Dosage Form
Solid, Semi-solid, External Liquid
PT Holi Pharma
High-Volume Manufacturing Backbone
Founded in 1968 and acquired by PYFA in 2021, Holi Pharma plays a vital role as the Group’s high-volume manufacturing backbone, specializing in generic medicines and essential supplements. With strong expertise in government tenders and national supply programs, Holi ensures cost-efficient production and consistent access to essential healthcare products across Indonesia.
Manufacturing Capacity & Capabilities
Location
Cimahi, West Java – Indonesia
Total Area
13,500 sqm
Buildings
2 Production Buildings
Facility Scope
Non-Beta Lactam
Dosage Form
Solid, Semi-solid, External Liquid
PT Ethica Industri Farmasi
Center of Excellence in Sterile & Injectable Manufacturing
Established in 1946, Ethica is Indonesia’s oldest injectable pharmaceutical manufacturer and a center of excellence in sterile production. Beyond its legacy, Ethica drives innovation through advanced formulations and holds exclusive rights to manufacture a New Chemical Entity (NCE), reinforcing its role as the Group’s core engine for complex and high-value pharmaceutical manufacturing.
Manufacturing Capacity & Capabilities
Location
Cikarang, West Java – Indonesia
Total Area
43,000 sqm
Buildings
5 Production Buildings
Facility Scope
Sterile – Small Volume
Dosage Form
Injectable Products
Probiotec (Australia)
Global Manufacturing & International Market Platform
Acquired as PYFA’s global manufacturing arm, Probiotec is a leading contract manufacturer operating across NSW and Victoria, Australia. Supported by advanced R&D capabilities, state-of-the-art facilities, and a prestigious international global pharmacy clients, that strengthens PYFA’s global footprint.
Manufacturing Capacity & Capabilities
Location
NSW & Victoria – Australia
Total Area
65,000 sqm
Buildings
6 Manufacturing & Packaging Entities
Facility Scope
Non-Beta Lactam & Co-Packaging
Dosage Form
Solid, Semi-Solid, Bottle & Probiotics & Co Packaging
Company Values (The Pylars)
Professional
Upholds quality standard to our business partners and customers
Innovation
Continuing to innovate in our products and services
Team Work
Support each other to achieve the best result
Agile
Ready to face various challenges
Milestone
PT Pyridam was founded by Ir. Sarkri Kosasih on November 27, 1976, based on Notarial Deed No. 31 by Tan Thong Kie in Jakarta, and initially focused on producing and marketing veterinary products through sales agents in several major cities across Indonesia.
The company diversified its business by producing and developing human medicines during the early stage of its expansion and was granted marketing rights by several overseas principals to distribute their medical equipment products in Indonesia, particularly in the laboratory equipment sector.
PT Pyridam veteriner was established to stay focused on the business of human medicine and laoratory apparatus/equipment.
Company built a factory (production facility) located in Desa Cibodas, Puncak, West Java.
The Company’s production factory began operations, and in the same year it conducted an IPO of 120,000,000 shares and was listed on the Jakarta Stock Exchange (now the Indonesia Stock Exchange). Following the IPO, the Company changed its name to PT Pyridam Farma Tbk. under Deed No. 267 dated December 23, 2000, approved by the Minister of Law and Human Rights of Indonesia.
The Company completed the preparation of Good Corporate Governance (GCG) in compliance with government regulations and relevant authorities, and published it on its website, including guidelines, board manual, code of conduct, risk management, audit committee charter, and internal audit unit charter.
Rejuve Global Investment Ltd acquired shares of PT Pyridam Farma Tbk, leading to changes in the company’s shareholder structure and management. In the same year, the company expanded into consumer health with the launch of its supplement brand, PYFAHEALTH.
The Company increased its ownership in PT Holi Pharma to nearly 100%, strengthening its pharmaceutical capabilities. In the same year, the Company expanded into the derma aesthetic segment with the launch of PYFAESTHETIC.
The Company acquired 100% ownership of PT Ethica Industri Farmasi, strengthening its manufacturing capabilities. In the same year, the Company launched Gerakan Sejuta Vitamin, an ESG-based initiative aimed at improving public health access.
The Company completed the acquisition of Probiotec through Pyfa Australia Pty Ltd, marking a key step in its international expansion. In the same year, the Company launched multiple new business units across beauty retail, CDMO, Marketing Authorization, and prescription segments under the brands PYFACDMO, PYFAMAH, and PYFARx.
The Company significantly expanded the production capacity of PT Ethica Industri Farmasi, enhancing overall manufacturing output and improving operational efficiency across the group.
